AOAlberto Olaya-Vargas

Alberto Olaya-Vargas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alberto Olaya-Vargas has a total of 293 co-authors. Here are the top co-authors by number of shared publications:

  • Martín Pérez-García

    Department of Hematopoietic Stem Cell Transplantation and Cell Therapy, Teleton Children’s Hospital for Oncology, Queretaro City, Mexico

    5 shared publications
  • Gerardo López-Hernández

    Department of Hematopoietic Stem Cell Transplantation and Cell Therapy, National Institute of Pediatrics, Mexico City, Mexico

    4 shared publications
  • Roberto Rivera-Luna

    Deparment of Oncology, National Institute of Pediatrics, Mexico City, Mexico

    4 shared publications
  • Armando Martínez-Avalos

    3 shared publications
  • Carlos Leal-Leal

    Division of Hem-Oncology, National Institute of Pediatrics (Instituto Nacional de Pediatría), Mexico City, Mexico

    3 shared publications
  • Haydee Salazar-Rosales

    Department of Hematopoietic Stem Cell Transplantation and Cell Therapy, National Institute of Pediatrics, Mexico City, Mexico

    3 shared publications

Latest Publications

  • Open Access

    Desarrollo y validez de contenido de una batería para evaluar factores asociados a la adherencia alimentaria en cuidadores de pacientes pediátricos postrasplante de células hematopoyéticas progenitoras

    by Diana Laura Hernández Ramos, Isaías Vicente Lugo González, Fatima Sagrario Espinoza Salgado, Alberto Olaya Vargas

    Introduction: Adherence to recommendations following hematopoietic progenitor cell transplantation (HPCT) is essential for preventing infections. In pediatric patients, food-handling practices are primarily the responsibility of parents, and perceived barriers and low self-efficacy may be associated with poorer adherence. Objective: To develop and evaluate the content validity of a battery designed to assess knowledge, self-efficacy, and barriers as factors associated with dietary adherence among parents of pediatric patients undergoing HPCT. Method: An instrumental study conducted in three phases: 1) initial development of the assessment battery, comprising three scales; 2) evaluation of content validity by a panel of expert judges using Aiken’s V, I-CVI, S-CVI/Ave, S-CVI/UA, and modified kappa (k*); and 3) selection, review, and modification of the items. Results: The initial version comprised 56 items, of which 42 simultaneously met the established criteria for content validity and inter-rater agreement (V ≥ 0.70; I-CVI according to the number of judges; k* ≥ 0.60). The remaining items were reviewed, rewritten, or eliminated based on the joint consideration of quantitative indicators and the experts’ qualitative comments. Overall, the three scales showed favorable content validity indices (S-CVI/Ave ≥ 0.90), except for the knowledge questionnaire regarding the clarity criterion (S-CVI/Ave = 0.84). Universal agreement (S-CVI/UA) yielded more conservative values, with clarity being the main aspect requiring semantic adjustment. After incorporating the modifications derived from the quantitative and qualitative evaluation, a final 53-item battery was obtained. Conclusions: The battery provides favorable initial evidence of content validity for assessing knowledge, self-efficacy, and barriers associated with dietary adherence among parents of pediatric patients undergoing HPCT. Further psychometric evaluation through pilot testing and subsequent studies in the target population is recommended.

  • Open Access

    A CAR/CD19 Jurkat cell model for bioprocess screening and expansion: potential use for CAR-T cells production

    by Hugo E. Fuentes-Bustos, Alejandrina Hernández-López, Marta Zapata-Tarrés, Juan Carlos Bustamante-Ogando, Blanca Angélica Segura-Pacheco, Alberto Olaya-Vargas, Angélica Meneses-Acosta

    Introduction: Cell expansion is one of the most critical steps in the development of CAR-T cell manufacturing processes because it directly influences cell yield and process performance. The systematic optimization of expansion parameters using primary human T cells is often limited by inter-donor variability, cost, and experimental complexity. So, it is necessary to study more homogeneous populations that allow to stablish standardized conditions in a controlled environment that were able to be used as standard. So, in this study, we developed a Jurkat CAR-CD19 cell-based platform as a reproducible model for optimizing the cell expansion bioprocess under controlled culture conditions. Methods: CAR-CD19-expressing Jurkat cells were pre-generated, molecularly characterized and subsequently used to evaluate key bioprocess variables, including glucose concentration, inoculum density, culture medium composition (RPMI + 10% FBS versus Nutri-T without serum), shaking speed, and different culture operating modes (batch, fed-batch, and semi-perfusion). Cell growth kinetics, metabolite consumption, metabolite production, and CAR expression were evaluated throughout the optimization process. Results: An intermediate glucose concentration supported cell expansion without additional benefit from higher glucose supplementation. Serum-free Nutri-T medium promoted higher viable cell densities than RPMI (used as control media) under the evaluated conditions. Among the operating modes evaluated, semi-perfusion achieved the highest viable cell density, maintaining high cell viability and a homogeneous CAR-positive cell population at the end of culture in Nutri-T media. Conclusion: These findings demonstrate that the Jurkat CAR-CD19 model provides a robust and reproducible experimental platform for optimizing cell expansion bioprocesses. While further validation in primary human CAR-T cells is required, this model allows for the systematic evaluation of culture variables, minimizing experimental variability and facilitating early-stage process development for adoptive cell therapies.

  • Open Access

    Analysis of sociodemographic factors, treatment abandonment, and prognosis of children with acute lymphoblastic leukemia in Mexico

    by Roberto Rivera Luna, Cesar Galván Diaz, Liliana Velasco-Hidalgo, Rocío Cardenas Cardos, Alberto Olaya Vargas, María Ximena García Vicera, Marco Aguilar Ortiz

    OBJECTIVE: To evaluate the impact of sociodemographic factors on diagnostic timeliness, treatment abandonment, and outcomes in pediatric ALL. MATERIALS AND METHODS: Descriptive, ecological study (2005–2018) merging official Mexican databases (INEGI, CENSIA, National Pediatric Cancer Registry) with cross-sectional surveys given to pediatric oncologists at accredited medical centers to assess referral times and treatment abandonment. RESULTS: Most public-sector patients live in social vulnerability and poverty. Mean referral time from clinical suspicion to specialized diagnosis was 9.4 days (range: 7–14). A wide geographic disparity in treatment abandonment emerged: baseline rates hovered near 5% across most centers, but spiked to 50–58% in southern/southeastern states, correlating with high social marginalization, language barriers, and limited infrastructure. CONCLUSIONS: Sociodemographic and access barriers compromise treatment adherence and overall survival. Integrating psychosocial and logistical support into care protocols is critical to prevent treatment abandonment and shrink outcome disparities.

  • Open Access

    Editorial: Immunological therapies in pediatric cancers: a Latin American perspective

    by Alberto Olaya-Vargas

    Immunotherapy has reshaped the global landscape of pediatric oncology, emerging as one of the most transformative therapeutic domains for children with relapsed, refractory, or high-risk malignancies. From bispecific antibodies to cell-based therapies and immunemodulating agents, these strategies-once confined to highly specialized centers in highincome countries-are now expanding into low-and middle-income regions. Latin America, a region marked by scientific talent but persistent structural inequalities, has entered a crucial phase in the adoption, evaluation, and local development of immunological therapies for childhood cancers.Despite economic, logistical, and regulatory challenges, a growing network of pediatric oncology centers across Mexico, Brazil, Argentina, Chile, and Colombia is advancing innovative models for implementing antibody-based therapies, post-transplant immune modulation, and emerging cellular therapies. These pioneering efforts not only address the clinical needs of the region but also generate evidence that reflects unique epidemiologic patterns, resource constraints, and population-specific disease biology. This special issue, Immunological Therapies in Pediatric Cancers: A Latin American Perspective, brings together a series of original contributions that illuminate the opportunities, challenges, and breakthroughs shaping the regional immunotherapy landscape. Each article offers a window into how Latin American institutions are reimagining care pathways for children with cancer through immunologic innovation.Highlights of the Special Issue 1. Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico This multicenter Mexican study demonstrates that the integration of blinatumomab as a bridge-to-transplant strategy can yield high remission rates and successful transition to haploidentical hematopoietic stem-cell transplantation (HSCT). The findings highlight both the feasibility and effectiveness of bispecific T-cell engager therapy in resource-limited settings while underscoring the growing regional expertise in haploidentical transplant platforms.2. High-risk neuroblastoma in Mexico: from multimodal therapy to immunotherapy-Experience with the first patient treated with naxitamabThe introduction of anti-GD2 immunotherapy in Mexico marks a milestone in the treatment of high-risk neuroblastoma. This case-based report contextualizes the first use of naxitamab in the country, illustrating how rigorous multimodal management combined with targeted immunotherapy can be successfully implemented in Latin American pediatric oncology units. It lays essential for broader national expansion of anti-GD2 treatment.3. Haploidentical, matched-related, and matched-unrelated donor HSCT for pediatric acute leukemias during the early years of haploidentical implementation in a developing country with a large donor registry This contribution provides a comparative experience across donor types during the initial phase of haploidentical transplant adoption. The study reveals encouraging outcomes for haploidentical HSCT, supported by the presence of a robust national unrelated donor registry. These observations reinforce the critical role of donor availability, local infrastructure, and early expertise in accelerating the growth of cellular therapy in middleincome countries.Post-transplant maintenance therapy is a rapidly evolving field, particularly in acute leukemias with high relapse risk. This Brazilian report provides real-world insight into maintenance strategies such as targeted agents, immune-modulating therapies, and precision-guided approaches tailored to relapse biology. The work reflects a growing Latin American commitment to extending curative potential beyond HSCT by adopting posttransplant immunologic interventions.This innovative investigation explores the anti-inflammatory and pro-apoptotic properties of pentoxifylline as an adjunctive immunomodulatory agent in ALL. The demonstration of early remission and enhanced leukemic apoptosis invites further exploration of costeffective, accessible immunologic strategies that may complement standard therapy in lowresource environments.Taken together, the contributions in this issue underscore a dynamic era for pediatric immuno-oncology in Latin America. Across diverse institutions, immunotherapy is increasingly viewed not as imported technology but as a domain ripe for regional innovation, clinical leadership, and context-specific solutions.However, significant challenges remain:-Equitable access to high-cost immunotherapies -Regulatory adaptability for advanced biologics and cell-based products -Sustainable financing models compatible with public health systems -Manufacturing capacity for CAR-T and other cell therapies -Specialized training to support rapidly evolving clinical technologies A Vision for the Future The rise of immunotherapy in Latin America is more than a scientific advancement-it is a movement toward health equity and therapeutic justice. As local experts implement and generate evidence for cutting-edge therapies, they redefine the global narrative of what is possible in pediatric oncology outside high-income settings. This special issue stands as a testament to the resilience, creativity, and scientific commitment that characterize pediatric oncology across the region. It invites researchers, clinicians, policymakers, and advocates to work collectively toward a future in which every child with cancer-regardless of geography-has access to life-saving immunological therapies.

  • Latin American Consensus on the Use of Anti-GD2 Monoclonal Antibody Therapy in Patients With High-Risk Neuroblastoma

    by Gabriela I. Villanueva, Sandra Alarcón, Diana Bonilla, Alejandra Casanovas, Mauricio Chaparro, Marcelo D. Coirini, Guido Felizzia, Diego Figueredo, Soad Fuentes-Alabi, Sima Ferman, et al.

    PURPOSE: To develop a Latin American expert consensus to support, guide, and accelerate the approval and equitable access to anti-GD2 immunotherapy for patients with high-risk neuroblastoma (HR-NB) in the region. Survival rates for HR-NB have improved with the incorporation of anti-GD2 immunotherapy; however, despite the approval of two commercial anti-GD2 therapies in two countries, access remains limited in Latin America. METHODS AND RESULTS: A systematic review was conducted of studies published from January 2004 through February 2025. Of 401 studies identified, 29 met inclusion criteria and served as the basis for four expert consensus statements on the use of anti-GD2 immunotherapy: (1) Newly diagnosed HR-NB maintenance therapy: Anti-GD2 immunotherapy as maintenance treatment for all newly diagnosed HR-NB patients is strongly recommended to maximize event-free survival and reduce the need for morbid and costly salvage therapies. (2) Relapsed/refractory NB: Early integration (at first relapse) of anti-GD2 immunotherapy in salvage treatment is recommended. (3) Role of high-dose chemotherapy with autologous stem-cell transplant (ASCT): Some argue that anti-GD2 immunotherapy obviates the need for ASCT. However, until results of randomized trials omitting ASCT are available, the panel recommends continued use of ASCT where it is available. (4) Newly diagnosed HR-NB: incorporation of anti-GD2 during induction/consolidation: Pilot studies using early anti-GD2 immunotherapy plus chemotherapy showed promising results but is not recommended until confirmed by larger studies with well-defined control arms. CONCLUSION: This consensus highlights the urgent need to expand access to anti-GD2 therapy in Latin America as maintenance therapy for newly diagnosed patients with HR-NB and patients with relapsed or refractory neuroblastoma. Collaboration between health policymakers, the pharmaceutical industry, the Global Platform for Access to Childhood Cancer Medicines, and the pediatric oncology community is essential to address this challenge.


  • Open Access

    Blinatumomab-induced remission followed by haploidentical transplantation in pediatric relapsed/refractory pre-B ALL: a multicenter study in Mexico

    by Alberto Olaya-Vargas, Haydee Salazar-Rosales, Yadira Melchor-Vidal, Martín Pérez-García, Annecy Herver-Olivares, Gerardo López-Hernández, Nideshda Ramírez-Uribe, Cesar Galván-Díaz, Irlanda Campos-Pérez, Pilar Cubria-Juárez, et al.

    Background: Precursor B-cell acute lymphoblastic leukemia (pre-B ALL) is the most common pediatric cancer worldwide, with cure rates exceeding 85% in high-income countries. However, in *Mexico*, event-free survival (EFS) during first remission remains below 65%. Children with *relapsed or refractory CD19+ pre-B ALL* have dismal prognoses and limited therapeutic options. This study evaluated the efficacy and safety of *blinatumomab* as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT), including *haploidentical HSCT*, in this high-risk population. Methods: This multicenter, prospective interventional study was conducted between February 2017 and December 2022 across four pediatric oncology centers in Mexico. Fifty-four patients (aged 8 months to 18 years) with refractory or high-risk relapsed CD19+ pre-B ALL received one or two cycles of *blinatumomab*. Responders were consolidated with allogeneic HSCT. Primary endpoints included remission rates and clinical factors associated with response; secondary endpoints were blinatumomab-related toxicity, overall survival (OS), EFS, and transplant outcomes. Results: Among 54 patients, 24 (44.5%) received one cycle, achieving a molecular complete remission rate of 75%. Thirty (55.5%) received two cycles, with 73.3% reaching deep remission (p = 0.89). Forty-one patients (76%) proceeded to HSCT, including 70% who received *haploidentical transplants*. Thirteen did not undergo HSCT due to refractory disease (n = 8) or partial response (n = 5). At 60 months, transplanted patients achieved an OS of 82% and EFS of 68%, with the best survival in matched related donor recipients (100%) versus haploidentical (58%). *Blinatumomab* demonstrated a favorable safety profile with no treatment-related mortality. Conclusion: Blinatumomab followed by haploidentical HSCT offers an effective and feasible therapeutic strategy for *relapsed or refractory CD19+ pre-B ALL* in *Mexico*, improving long-term survival in resource-limited settings.


  • Open Access

    High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab

    by Alberto Olaya Vargas, Haydee Salazar-Rosales, Marcela Caballero-Palacios, Nideshda Ramírez-Uribe, Gerardo López-Hernández, Erika Morales-Martinez, María Cervantes-Delgado, Liliana Velasco Hidalgo, Araceli Castellanos-Toledo, Rocío Cárdenas-Cardos, et al.

    Introduction: We report herein the case of a patient diagnosed with high-risk neuroblastoma (HR-NB), treated with naxitamab following suboptimal response to induction chemotherapy, becoming the first patient to receive this therapy at the National Institute of Pediatrics (INP) in Mexico. We discuss the clinical course, therapeutic approach, response to treatment, adverse events, and fatal outcome, focusing on the implications of immunotherapy access in low- and middle-income countries (LMIC).Case presentation: A 2-year-old male presented with a 3-month history of a left front-temporal mass and left-sided exophthalmos. Magnetic resonance imaging (MRI) revealed a poorly defined retroperitoneal and paravertebral mass, and a destructive cranial lesion involving the sphenoid wing and the orbit. PET-CT and MIBG scans confirmed widespread metastatic disease in bone, orbit, and intracranial structures, consistent with stage 4 neuroblastoma. Histopathology of a cranial biopsy confirmed poorly differentiated neuroblastoma. The patient was classified as high-risk based on age and metastatic disease, and underwent multimodal treatment including chemotherapy, partial tumor resection, radiotherapy, and anti-GD2 immunotherapy with naxitamab under protocol HITS-17-251. After five cycles, imaging showed complete response in cranial metastases. Adverse events during immunotherapy were mild (Grade I–II), including erythema, pruritus, urticaria, and transient hypotension, all managed with antihistamines and IV fluids. However, one month after the final cycle, the patient developed sudden neurological deterioration with cerebral edema and hydrocephalus. Despite intensive care, he progressed to brain death, with neurotoxicity suspected as the cause.Discussion: The primary objective of implementing novel immunotherapeutic strategies, in addition to improving event-free survival (EFS) and overall survival (OS) in patients diagnosed with high-risk neuroblastoma, is to reduce adverse effects and lower both short- and long-term mortality. It is worth noting that the current cost of anti-GD2 therapies available in Latin America is estimated to exceed $450,000 USD. In a country like Mexico, where the minimum daily wage is approximately $10 USD, access to these therapies remains unattainable for the majority of the population. Therefore, it is essential to highlight the importance and substantial clinical impact of immunotherapy on survival outcomes in patients with refractory neuroblastoma. This recognition should support advocacy for broader access to these therapies. Despite their high costs, the demonstrated benefits should outweigh the disadvantages, justifying efforts to make them accessible to all patient populations.Conclusions: Future studies in LMICs including Mexico and Latin America, must focus on optimizing dosing strategies to minimize adverse effects and improve both survival outcomes and the quality of life for patients receiving immunotherapy.


  • Open Access

    Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases

    by Alejandrina Hernández-López, Alberto Olaya-Vargas, Juan Carlos Bustamante-Ogando, Angélica Meneses-Acosta

    CAR-T cell therapy has shown promising results in treating malignant hematologic diseases. The principle of this therapy is based on the use of genetically modified T lymphocytes to express a Chimeric Antigen Receptor (CAR) on their membrane that specifically recognizes an antigen predominantly expressed on target cells. The molecular design of the CAR, along with advancements in molecular techniques and the development of “omics”, has opened the possibility of discovering new therapeutic targets and thereby expanding the range of diseases treated with CAR-T cells beyond the use of anti-CD19 and anti-BCMA for hematologic cancer. This review summarizes the novel therapeutic targets that are currently used in clinical trials with CAR-T cell therapy on autoimmune diseases and other challenging conditions, such as cardiac fibrosis, and different infections. Additionally, challenges and novel opportunities are discussed for expanding clinical access to this innovative therapy.


  • Open Access

    Selective Inhibition of Deamidated Triosephosphate Isomerase by Disulfiram, Curcumin, and Sodium Dichloroacetate: Synergistic Therapeutic Strategies for T-Cell Acute Lymphoblastic Leukemia in Jurkat Cells

    by Luis A. Flores-López, Ignacio De la Mora-De la Mora, Claudia M. Malagón-Reyes, Itzhel García-Torres, Yoalli Martínez-Pérez, Gabriela López-Herrera, Gloria Hernández-Alcántara, Gloria León-Avila, Gabriel López-Velázquez, Alberto Olaya-Vargas, et al.

    T-cell acute lymphoblastic leukemia (T-ALL) is a challenging childhood cancer to treat, with limited therapeutic options and high relapse rates. This study explores deamidated triosephosphate isomerase (dTPI) as a novel therapeutic target. We hypothesized that selectively inhibiting dTPI could reduce T-ALL cell viability without affecting normal T lymphocytes. Computational modeling and recombinant enzyme assays revealed that disulfiram (DS) and curcumin (CU) selectively bind and inhibit dTPI activity without affecting the non-deamidated enzyme. At the cellular level, treatment with DS and CU significantly reduced Jurkat T-ALL cell viability and endogenous TPI enzymatic activity, with no effect on normal T lymphocytes, whereas the combination of sodium dichloroacetate (DCA) with DS or CU showed synergistic effects. Furthermore, we demonstrated that dTPI was present and accumulated only in Jurkat cells, confirming our hypothesis. Finally, flow cytometry confirmed apoptosis in Jurkat cells after treatment with DS and CU or their combination with DCA. These findings strongly suggest that targeting dTPI represents a promising and selective target for T-ALL therapy.


  • Open Access

    Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro

    by María del Pilar Navarrete-Meneses, Consuelo Salas-Labadía, María del Rocío Juárez-Velázquez, Dafné Moreno-Lorenzana, Fernando Gómez-Chávez, Alberto Olaya-Vargas, Patricia Pérez-Vera

    The evidence supporting the biological plausibility of the association of permethrin and malathion with hematological cancer is limited and contradictory; thus, further studies are needed. This study aimed to investigate whether in vitro exposure to 0.1 μM permethrin and malathion at 0, 24, 48 and 72 h after cell culture initiation induced changes in the gene expression and DNA methylation in mononuclear cells from bone marrow and peripheral blood (BMMCs, PBMCs). Both pesticides induced several gene expression modifications in both tissues. Through gene ontology analysis, we found that permethrin deregulates ion channels in PBMCs and BMMCs and that malathion alters genes coding proteins with nucleic acid binding capacity, which was also observed in PBMCs exposed to permethrin. Additionally, we found that both insecticides deregulate genes coding proteins with chemotaxis functions, ion channels, and cytokines. Several genes deregulated in this study are potentially associated with cancer onset and development, and some of them have been reported to be deregulated in hematological cancer. We found that permethrin does not induce DNA hypermethylation but can induce hypomethylation, and that malathion generated both types of events. Our results suggest that these pesticides have the potential to modify gene expression through changes in promoter DNA methylation and potentially through other mechanisms that should be investigated.